KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Work In Process (2016 - 2017)

Amgen has reported Work In Process over the past 5 years, most recently at $1.6 billion for Q2 2017.

  • For Q2 2017, Work In Process changed N/A year-over-year to $1.6 billion; the TTM value through Jun 2017 reached $1.6 billion, changed N/A, while the annual FY2016 figure was $1.6 billion, 5.17% up from the prior year.
  • Work In Process for Q2 2017 was $1.6 billion at Amgen, up from $1.5 billion in the prior quarter.
  • Over five years, Work In Process peaked at $2.1 billion in Q4 2013 and troughed at $1.3 billion in Q2 2015.
  • A 5-year average of $1.6 billion and a median of $1.6 billion in 2014 define the central range for Work In Process.
  • Biggest five-year swings in Work In Process: dropped 28.1% in 2015 and later grew 5.17% in 2016.
  • Year by year, Work In Process stood at $2.1 billion in 2013, then fell by 24.85% to $1.6 billion in 2014, then dropped by 1.42% to $1.5 billion in 2015, then grew by 5.17% to $1.6 billion in 2016, then rose by 0.62% to $1.6 billion in 2017.
  • Business Quant data shows Work In Process for AMGN at $1.6 billion in Q2 2017, $1.5 billion in Q1 2017, and $1.6 billion in Q4 2016.